NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.54 CHF | +0.85% |
|
+1.67% | +6.68% |
| 06/05 | NOVARTIS AG : UBS maintains a Buy rating | ZD |
| 02/05 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
Presentation Operator MessageOperator (Operator)Good morning, and good afternoon, and welcome ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
99.69
USD
Average target price
108.4
USD
Spread / Average Target
+8.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.68% | 202B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Transcript : Novartis AG, Q3 2023 Earnings Call, Oct 24, 2023